Combination Therapy Using c-Met and IGF-1R Inhibitors

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Cancer treatments using single-target drugs often face resistance and limited therapeutic effects, necessitating a combination therapy targeting multiple pathways to overcome resistance and expand treatment scope.

Innovation Solution

Co-administration of a c-Met inhibitor and an IGF-1R inhibitor to simultaneously target c-Met and IGF-1R, with IGF-1R serving as a marker for resistance to c-Met inhibitors, allowing for expanded therapeutic effects and overcoming resistance.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If a single-target drug (c-Met inhibitor) is used for cancer treatment, then the treatment is simple and has fewer side effects, but resistance develops and therapeutic effect is limited

Engineering Contradiction:

Improvetherapeutic effectVSAvoidresistance to treatment

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent combines c-Met inhibitor and IGF-1R inhibitor into a dual-target therapy regimen. This merging of two targeting drugs simultaneously blocks both c-Met and IGF-1R signaling pathways, preventing cancer cells from developing resistance through alternative pathway activation while maintaining simplified administration protocols

Inventive Principle:

Principle #5Merging (Combining)

2Adaptability or versatility

If combination therapy with multiple targeting drugs is used, then resistance is overcome and therapeutic effect is enhanced, but treatment complexity and side effects increase

Engineering Contradiction:

Improveovercoming resistanceVSAvoidtreatment complexity

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent identifies IGF-1R as a universal target that addresses multiple problems simultaneously: it serves as both a therapeutic target for combination therapy and as a biomarker for predicting c-Met inhibitor resistance. This multi-functionality allows a single additional drug to provide both treatment enhancement and resistance prevention without proportionally increasing complexity

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Reliability

If higher doses of c-Met inhibitor are administered to overcome resistance, then therapeutic effect improves, but side effects increase

Engineering Contradiction:

Improvetherapeutic effectVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the therapeutic parameter from single-drug dosage optimization to dual-drug combination dosing. By introducing IGF-1R inhibitor at appropriate doses alongside c-Met inhibitor, the regimen achieves enhanced therapeutic effect through pathway dual-blockade while maintaining lower individual drug doses, thereby reducing toxicity compared to high-dose monotherapy

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS10064939B2Combination therapy using c-Met inhibitor and IGF-1R inhibitor for c-Met inhibitor resistant cancers

Publication Date: 2018.09.04 SAMSUNG ELECTRONICS CO LTD

AI summary

A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met (hereinafter, ‘c-Met inhibitor’) and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met inhibitor.